• 
  Dana Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.298. ⟨10.1186/s13063-023-07294-0⟩. ⟨hal-04176626⟩
• 
  Anna Gueiderikh, Thomas Sarrade, Youlia M. Kirova, Brigitte de la Lande, Florent de Vathaire, et al.. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors. Frontiers in Oncology, 2023, 13, ⟨10.3389/fonc.2023.1199043⟩. ⟨hal-04195134⟩
• 
  Pierre Decazes, Samy Ammari, Antoine de Prévia, Léo Mottay, Littisha Lawrance, et al.. Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs. Diagnostics, 2023, 13 (2), pp.205. ⟨10.3390/diagnostics13020205⟩. ⟨hal-04175332⟩
• 
  Dana M Hartl, Yann Godbert, Xavier Carrat, Stéphane Bardet, Audrey Lasne-Cardon, et al.. Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial. Trials, 2023, 24 (1), pp.452. ⟨10.1186/s13063-023-07467-x⟩. ⟨inserm-04526673⟩
• 
  M Tonneau, R Nebbache, A Larnaudie, S Thureau, Y Pointreau, et al.. Management of head and neck carcinomas with synchronous or metachronous oligometastatic disease: Role of locoregional radiotherapy and metastasis-directed radiotherapy. Cancer/Radiothérapie, 2024, 28 (1), pp.83-92. ⟨10.1016/j.canrad.2023.03.004⟩. ⟨hal-04441453⟩
• 
  Xavier Pivot, Gilles Romieu, Pierre Fumoleau, Maria Rios, Hervé Bonnefoi, et al.. Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort. npj Breast Cancer, 2017, 3 (1), pp.4. ⟨10.1038/s41523-017-0005-y⟩. ⟨cea-04501580⟩
• 
  Pierre Decazes, Samy Ammari, Younes Belkouchi, Léo Mottay, Littisha Lawrance, et al.. Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer. Journal for Immunotherapy of Cancer, 2023, 11 (9), pp.e007315. ⟨10.1136/jitc-2023-007315⟩. ⟨hal-04287256⟩
• 
  Stéphane Culine, Valentin Harter, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, et al.. Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩. ⟨hal-03625944⟩
• 
  Blandine Truffault, David Bourhis, Anne Chaput, Jérémie Calais, Philippe Robin, et al.. Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse : Impact of Treatment Position and Images Registration Method. Frontiers in Medicine, 2020, 7, pp.218. ⟨10.3389/fmed.2020.00218⟩. ⟨hal-02922556⟩
• 
  Jennifer Le Guevelou, Colin Debaigt, Esma Saada-Bouzid, Julien Viotti, Nazim Khalladi, et al.. Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol.. BMJ Open, 2020, BMJ Open, 10, pp.e038391. ⟨10.1136/bmjopen-2020-038391⟩. ⟨hal-04346738⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. The Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Brice Paquette, Dewi Vernerey, Bruno Chauffert, Sandrine Dabakuyo, Loic Feuvret, et al.. Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma. Cancer Medicine, 2016, 5 (8), pp.1753-1764. ⟨10.1002/cam4.734⟩. ⟨hal-03036055⟩
• 
  Anne‐sophie Baudry, Sonya Yakimova, Anne Congard, Aurélie Untas, Séverine Guiu, et al.. Adjustment of young women with breast cancer after chemotherapy: A mediation model of emotional competence via emotional distress. Psycho-Oncology, 2022, 31 (5), pp.848-855. ⟨10.1002/pon.5876⟩. ⟨hal-03771024⟩
• 
  Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier Chinot, Maryline Barrie, Luc Taillandier, et al.. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23 (5), pp.524-e44. ⟨10.1634/theoncologist.2017-0689⟩. ⟨hal-01727451⟩
• 
  Raphael Itzykson, Elise Fournier, Celine Berthon, Christoph Rollig, Thorsten Braun, et al.. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138 (7), pp.507-519. ⟨10.1182/blood.2021011103⟩. ⟨hal-03606388⟩
• 
  P. Pautier, A. Floquet, C. Chevreau, N. Penel, C. Guillemet, et al.. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open, 2021, 6 (4), pp.100209. ⟨10.1016/j.esmoop.2021.100209⟩. ⟨hal-03623631⟩
• 
  Joël Castelli, Juliette Thariat, Karen Benezery, Ali Hasbini, Bernard Gery, et al.. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer. JAMA oncology, 2023, pp.e231352. ⟨10.1001/jamaoncol.2023.1352⟩. ⟨hal-04117942⟩
• 
  Nicolas Penel, Sylvie Bonvalot, Marie Cécile Le Deley, Antoine Italiano, Camille Tlemsani, et al.. Pain in desmoid-type fibromatosis: Prevalence, determinants and prognosis value. International Journal of Cancer, 2023, 153 (2), pp.407-416. ⟨10.1002/ijc.34493⟩. ⟨hal-04106296⟩
• 
  Antonio Di Meglio, Julie Havas, Davide Soldato, Daniele Presti, Elise Martin, et al.. Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. Journal of Clinical Oncology, 2022, 40 (10), pp.1111--1123. ⟨10.1200/JCO.21.01252⟩. ⟨hal-03855945⟩

99

408